LuoFuShan Rheumatism Plaster ameliorates neuropathic pain in mice by suppressing TLR4/TNF-α signaling.
10.12122/j.issn.1673-4254.2025.11.01
- Author:
Yufang FU
1
;
Weiling TAN
1
;
Xiaocui LI
1
;
Rongtian LIN
2
;
Shuwen LIU
1
;
Ling YE
1
Author Information
1. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
2. Guangdong Engineering Research Center for Anti-Rheumatic Traditional Chinese Medicine, R&D Center, Guangdong Luofushan Sinopharm Co., Ltd., Huizhou 516100, China.
- Publication Type:Journal Article
- Keywords:
LuoFuShan Rheumatism Plaster;
Safety evaluation;
TLR4/TNF-α signaling;
neuropathic pain
- MeSH:
Animals;
Toll-Like Receptor 4/metabolism*;
Neuralgia/metabolism*;
Mice;
Signal Transduction/drug effects*;
Tumor Necrosis Factor-alpha/metabolism*;
Drugs, Chinese Herbal/pharmacology*;
Sciatic Nerve/injuries*;
Male;
Molecular Docking Simulation;
Disease Models, Animal;
Interleukin-6
- From:
Journal of Southern Medical University
2025;45(11):2285-2296
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To explore the therapeutic effect of LuoFuShan Rheumatism Plaster (LFS) on neuropathic pain (NP) and its molecular mechanism.
METHODS:Mouse models of sciatic nerve chronic constriction injury (CCI) were treated with low, medium, and high doses (2.2, 4.4, and 8.8 cm2, respectively) of LFS by topical application for 14 consecutive days. The therapeutic effects were assessed by evaluating the mechanical withdrawal threshold (MWT), paw withdrawal latency (PWL), plasma IL-6 and TNF-α levels, and histopathology of the sciatic nerve. Network pharmacology and molecular docking were used to identify the key targets and signaling pathways. The key targets were verified by RT-qPCR and immunohistochemistry. The biosafety of LFS was evaluated by measuring the organ indices and damage indicators of the heart, liver, and kidneys.
RESULTS:Compared with the CCI group, LFS dose-dependently increased MWT and PWL, reduced plasma IL-6 and TNF-α levels, and alleviated sciatic nerve inflammation in the mouse models. Network pharmacology identified 378 bioactive compounds targeting 279 NP-associated genes enriched in TLR and TNF signaling. Molecular docking showed that quercetin and ursolic acid in LFS could stably bind to TLR4 and TNF‑α. In the mouse models of sciatic nerve CCI, LFS significantly downregulated the mRNA expression levels of Tlr4 and Tnf-α in the spinal cord in a dose-dependent manner and lowered the protein expressions of TLR4 and TNF-α in the sciatic nerve. LFS treatment did not cause significant changes in the organ indices or damage indicators of the heart, liver and kidneys as compared with those in the CCI model group and sham-operated group.
CONCLUSIONS:LFS alleviates NP in mice by suppression of TLR4/TNF-α-mediated neuroinflammation with a good safety profile.
